The new eyedrop raises hopes for less invasive treatment of serious vision conditions

The new EYE -Cedrop showed early success in providing protective compounds to the place where they are most needed in the eye, raising hopes for less invasive treatment of serious vision conditions.

Research conducted by Rmit University focuses especially on retinal diseases Age -related macular degeneration (AMD). AMD damages retina, in particular a stain, which can cause blindness and affects hundreds of millions of people around the world.

AMD’s key risk factors are age, family history, diet, high blood pressure, obesity, smoking and other lifestyle choices.

In the modern era we have an exposure to excessive blue light with high energy from devices such as mobile phones, computer screens and TVs, which can also contribute to eye damage over time.

The team examined the supply of lutein, a protective antioxidant compound found in GAC fruits, at the back of the eye to support volleyball and potentially slow or prevent damage.

In the research of pre-clinical mice carried out in cooperation with the Center for Eye Research Australia (complexion), the formula reached the retina at the back of the eye-currently available only through injections-and maintained the stability of the active compound for months at room temperature.

The syndrome’s cellular breeding study showed that lutein supplied a new retinal cell preparation against stress and damage associated with eye loss.

Dr. Dao Nguyen, who, co -founder of research, when she was in Rmit, said that the wording could pave the way for patients -friendly therapy.

“Frequent eye injections are uncomfortable and may be disturbing for patients. If the preparation works, people could use Eyeedrop as a preventive measure that could reduce the risk of developing late stage diseases and the need for injections,” said Nguyen, who is currently at the school of Deakin University.

“Our Eyedrop formula is aimed at treating the early stages of age -related macular degeneration in a much easier way to use, but this will take further clinical examinations and clinical trials before it reaches people.”

Nguyen said that the feeders do not replace injections.

The leader of the team Professor Professor Tien Hynh from Rmit’s School of Science said that the delivery platform can be adapted to wearing various compounds, not just the tested in this study.

“This is a technology with a wide potential. We have shown that it can protect fragile ingredients and safely transfer them to the back of the eye, which has long been a barrier to treatments,” said Hignh.

Professor Charlotte Conn and Dr. Sampa Sarkar, the main researchers of the innovative delivery method, said that nanotechnology called Cubosomes in order to provide drugs turned out to be the early promise of this and a number of other use of drugs.

Our Cubosome carriers act like small shields, maintaining a safe relationship and releasing them in a controlled way when they are in the eye. ”

Professor Charlotte Conn, Rmit’s School of Science

Professor Chi Luu, a clinicist-scientist in complexion and University of Melbourne, said the results were encouraging.

“This kind of approach can transform the way we deal with age -related macular degeneration. If future attempts confirm the safety and effectiveness of the delivery platform, Eye Eye may be one day used for the treatment of early AMD stages and other serious retinal diseases,” said Luu.

Scientists note that work is still at an early stage: the results come from cellular tests and animals, and the experiments have not checked whether the preparation improved the results of the disease, because the mice did not have AMD or any other retina.

The next step is cooperation with clinical and industry partners to further test the formula and transfer it to people’s research.

Study: “Optimization of lutein preparations for targeted delivery of the eye: in vitro and in vivo insights”, were published in a reviewed magazine (DOI: 10.1021/acsami.5c1464).

Other co -authors of the study were Dr. Thilini Thrimavithan and Professor Terrence Piva.

A recent review of literature from the team, headed by Rmit Christopher Olowosoke, emphasizes the promise of plant relationships, including Lutein, to protect eye health.

Studies “Non-invasive pharmacological progress in early treatment of retinopathy: bioactive herbal compounds, polymer supply systems and computational biopounting of functional goals” are published in a reviewed magazine (DOI: 10.1007/s43440-025-00778-7).